Takayuki Sumiyoshi

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts et al. · Nature Communications · 2024 · 120 citations · Full text

Medicine, Biostatistics, Oncology +17

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer

Takayuki Sumiyoshi, Kei Mizuno, Toshinari Yamasaki et al. · Scientific Reports · 2019 · 74 citations · Full text

Medicine, Genetics, Oncology +17

Association of Missense Polymorphism in<i>HSD3B1</i>With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone

Masaki Shiota, Shintaro Narita, Shusuke Akamatsu et al. · JAMA Network Open · 2019 · 62 citations · Full text

Medicine, Endocrinology, Genetics +15

<scp>CCL</scp>2 as a potential therapeutic target for clear cell renal cell carcinoma

Ryuichiro Arakaki, Toshinari Yamasaki, Toru Kanno et al. · Cancer Medicine · 2016 · 61 citations · Full text

Medicine, Cell Biology, Oncology +17

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Sofie H. Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi et al. · Clinical Cancer Research · 2023 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17